Thus, in our tumor xenograft model established from trastuzumab-resistant BT-474.r2T cells, HER2-directed therapy with trastuzumab in combination with verteporfin led to a significant inhibition of tumor growth and cell proliferation, and stimulation of apoptosis. The gene discussed is ERBB2; the disease is neoplasm.